Refining the Benefit–Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters | Zendy

Walker S | Zendy; Liberti L | Zendy; McAuslane N | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Refining the Benefit–Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters

Author(s) -

Walker S,

Liberti L,

McAuslane N

Publication year - 2011

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2010.290

Subject(s) - weighting , product (mathematics) , stakeholder , risk analysis (engineering) , clinical pharmacology , computer science , management science , medicine , pharmacology , engineering , mathematics , economics , geometry , management , radiology

A common framework is necessary for the transparent articulation of the benefits and risks of a therapeutic product across disparate stakeholders. The assignment of value and weighting to each component parameter presents challenges deriving from different stakeholder objectives, methods, and perspectives. Building on prior experiences with a validated framework approach, this forum focused on identifying challenges and approaches to the assignment of values and weightings using a case study applied to a hypothetical medicinal product. Clinical Pharmacology & Therapeutics (2011) 89 2, 179–182. doi: 10.1038/clpt.2010.290

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research